| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $5,031,308 | 9 | 100 |
| Hollywood Mark | EVP & Chief Operating Officer | 0 | $0 | 1 | $138,762 | $-138,762 |
| Schayowitz Adam | EVP, Head of R&D | 0 | $0 | 1 | $357,557 | $-357,557 |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 0 | $0 | 2 | $475,561 | $-475,561 |
| Moore Paul Andrew | Chief Scientific Officer | 0 | $0 | 2 | $721,457 | $-721,457 |
| Galbraith Kenneth | Chair & CEO | 0 | $0 | 3 | $3.34M | $-3.34M |
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human …
Over the last 12 months, insiders at Zymeworks Inc. have bought $0 and sold $5.03M worth of Zymeworks Inc. stock.
On average, over the past 5 years, insiders at Zymeworks Inc. have bought $35.87M and sold $1.37M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,919 shares for transaction amount of $69,738 was made by EcoR1 Capital, LLC () on 2025‑05‑19.
| 2026-10-09 | Sale | Schayowitz Adam | EVP, Head of R&D | 13,832 0.0188% | $25.85 | $357,557 | +9.42% | |
| 2026-01-12 | Sale | Galbraith Kenneth | Chair & CEO | 30,424 0.0396% | $22.67 | $689,819 | +7.66% | |
| 2026-01-12 | Sale | Hollywood Mark | EVP & Chief Operating Officer | 6,120 0.008% | $22.67 | $138,762 | +7.66% | |
| 2026-01-12 | Sale | Moore Paul Andrew | Chief Scientific Officer | 9,560 0.0124% | $22.67 | $216,759 | +7.66% | |
| 2026-01-12 | Sale | Smith Jeffrey T L | EVP & Chief Medical Officer | 9,310 0.0121% | $22.67 | $211,090 | +7.66% | |
| 2026-01-05 | Sale | Galbraith Kenneth | Chair & CEO | 54,343 0.0712% | $25.10 | $1.36M | -2.51% | |
| 2026-01-05 | Sale | Moore Paul Andrew | Chief Scientific Officer | 20,110 0.0263% | $25.10 | $504,699 | -2.51% | |
| 2026-01-05 | Sale | Smith Jeffrey T L | EVP & Chief Medical Officer | 10,538 0.0138% | $25.10 | $264,471 | -2.51% | |
| 2025-12-22 | Sale | Galbraith Kenneth | Chair & CEO | 47,528 0.0618% | $27.02 | $1.28M | -9.38% | |
| 2025-05-19 | EcoR1 Capital, LLC | 5,919 0.0085% | $11.78 | $69,738 | +86.29% | |||
| 2025-05-15 | EcoR1 Capital, LLC | 49,502 0.0704% | $11.43 | $565,847 | +68.08% | |||
| 2025-04-17 | EcoR1 Capital, LLC | 54,760 0.0869% | $11.52 | $630,819 | +55.38% | |||
| 2025-04-16 | EcoR1 Capital, LLC | 73,953 0.1138% | $11.16 | $825,589 | +58.40% | |||
| 2025-04-04 | EcoR1 Capital, LLC | 196,438 0.288% | $11.17 | $2.19M | +54.34% | |||
| 2025-04-03 | EcoR1 Capital, LLC | 120,770 0.1749% | $11.84 | $1.43M | +42.89% | |||
| 2025-04-02 | EcoR1 Capital, LLC | 74,360 0.1062% | $11.85 | $881,017 | +39.93% | |||
| 2025-04-01 | EcoR1 Capital, LLC | 48,658 0.0698% | $11.60 | $564,647 | +43.55% | |||
| 2025-03-31 | EcoR1 Capital, LLC | 4,397 0.0062% | $11.75 | $51,658 | +39.38% | |||
| 2025-03-26 | EcoR1 Capital, LLC | 43,848 0.0625% | $12.24 | $536,857 | +33.52% | |||
| 2025-03-25 | EcoR1 Capital, LLC | 53,501 0.0775% | $12.91 | $690,452 | +28.59% |
| EcoR1 Capital, LLC | 17883908 24.8733% | $538.84M | 45 | 0 | +16.56% | |
| Redmile Group, LLC | 10 percent owner | 6075918 8.4505% | $183.07M | 1 | 0 | +63.8% |
| Tehrani Ali | Chief Executive Officer | 260325 0.3621% | $7.84M | 1 | 6 | +12.44% |
| Josephson Neil | Chief Medical Officer | 14449 0.0201% | $435,348.37 | 1 | 1 | <0.0001% |
| Cox Troy | director | 7500 0.0104% | $225,975.00 | 1 | 0 | <0.0001% |
$21,345,882 | 83 | 94.45% | $2.19B | |
$47,419,530 | 58 | 17.20% | $1.96B | |
$1,376,668 | 53 | 18.46% | $2.1B | |
Zymeworks Inc. (ZYME) | $108,353,116 | 49 | 15.41% | $2.17B |
$61,893,001 | 38 | 19.63% | $1.89B |
| Increased Positions | 118 | +58.71% | 12M | +16.2% |
| Decreased Positions | 86 | -42.79% | 14M | -19.14% |
| New Positions | 47 | New | 6M | New |
| Sold Out Positions | 24 | Sold Out | 3M | Sold Out |
| Total Postitions | 233 | +15.92% | 72M | -2.95% |
| Ecor1 Capital, Llc | $611,472.00 | 30.63% | 22.97M | 0 | 0% | 2025-09-30 |
| Rubric Capital Management Lp | $125,395.00 | 6.28% | 4.71M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $106,201.00 | 5.32% | 3.99M | +195,261 | +5.15% | 2025-09-30 |
| Morgan Stanley | $106,070.00 | 5.31% | 3.98M | -193,029 | -4.62% | 2025-09-30 |
| Bvf Inc/Il | $104,847.00 | 5.25% | 3.94M | -370,294 | -8.59% | 2025-09-30 |
| Redmile Group, Llc | $98,647.00 | 4.94% | 3.71M | -444,877 | -10.72% | 2025-09-30 |
| Vanguard Group Inc | $57,351.00 | 2.87% | 2.15M | -310,259 | -12.59% | 2025-09-30 |
| Perceptive Advisors Llc | $55,653.00 | 2.79% | 2.09M | +815,389 | +63.94% | 2025-09-30 |
| Vestal Point Capital, Lp | $46,984.00 | 2.35% | 1.76M | +615,000 | +53.48% | 2025-09-30 |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Ame | $45,533.00 | 2.28% | 1.71M | -749,050 | -30.45% | 2025-09-30 |